Collegium Pharmaceutical, Inc 8-K Filing

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
• $580,000,000 — The Credit Agreement provides for (i) a $580,000,000 term loan, (ii) $300,000,000 of delayed
• $300,000,000 — for (i) a $580,000,000 term loan, (ii) $300,000,000 of delayed draw term loan commitments,
• $100,000,000 — draw term loan commitments, and (iii) a $100,000,000 revolving credit facility. The initial
• $250,000,000 — nant (allowing the Company to net up to $250,000,000 of unrestricted cash and cash equivalen

Filing Documents

• tm2534421d1_8k.htm (8-K) — 27KB
• tm2534421d1_ex99-1.htm (EX-99.1) — 13KB
• tm2534421d1_ex99-1img01.jpg (GRAPHIC) — 17KB
• 0001104659-25-125026.txt ( ) — 231KB
• coll-20251223.xsd (EX-101.SCH) — 3KB
• coll-20251223_lab.xml (EX-101.LAB) — 33KB
• coll-20251223_pre.xml (EX-101.PRE) — 22KB
• tm2534421d1_8k_htm.xml (XML) — 3KB

01 Entry into a Material Agreement

Item 1.01 Entry into a Material Agreement. On December 23, 2025, Collegium Pharmaceutical, Inc. (the "Company") entered into a Credit Agreement by and among the Company, the lenders from time to time party thereto and Truist Bank, as administrative agent (the "Credit Agreement"). The Credit Agreement provides for (i) a $580,000,000 term loan, (ii) $300,000,000 of delayed draw term loan commitments, and (iii) a $100,000,000 revolving credit facility. The initial Term Loan was used to repay in full the remaining outstanding obligations under the Company's Second Amended and Restated Loan Agreement, dated as of July 28, 2024, by and among the Company, the loan parties party thereto, the lenders party thereto, and Biopharma Credit PLC, as collateral agent (the "Existing Credit Agreement"), to pay fees and expenses relating to the entry into the Credit Agreement and the remainder for general corporate purposes. Loans under the Credit Agreement will bear interest at an annual rate equal to the term Secured Overnight Financing Rate ("SOFR") plus a spread based on the Company's First Lien Net Leverage Ratio (as defined in the Credit Agreement) ranging from 2.75% to 3.75%. The Credit Agreement contains a customary array of representations, events of default and covenants for a syndicated credit facility. The Credit Agreement includes quarterly tested financial covenants, consisting of a first lien secured net leverage ratio maintenance covenant (allowing the Company to net up to $250,000,000 of unrestricted cash and cash equivalents) and a customary fixed charge coverage ratio maintenance covenant. The Company is obligated to repay the loans under the Credit Agreement (i) in scheduled quarterly instalments, commencing on March 31, 2026, and (ii) upon certain customary prepayment triggers (subject to customary reinvestment rights). The Company may repay the loans under the Credit Agreement at its option at any time without premium or penalty. The foregoing description of

02 Termination of a Material Agreement

Item 1.02 Termination of a Material Agreement. The information set forth under Item 1.01 with respect to the repayment of the Existing Credit Agreement is incorporated herein by reference. On December 23, 2025, in connection with its entry into the Credit Agreement, the Company repaid in full all obligations outstanding under the Existing Credit Agreement. Upon repayment, (i) all outstanding obligations under the Existing Credit Agreement were paid in full, including the applicable prepayment premium and make-whole amount due thereunder in connection with the repayment; (ii) all commitments thereunder were terminated; and (iii) all liens and security interests securing the obligations under the Existing Credit Agreement were released pursuant to a customary payoff letter.

02 Creation of a Direct Financial Obligation or an Obligation

Item 3.02 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 is incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 30, 2025, the Company issued a press release announcing its entry into the Credit Agreement. The press release is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Colleen Tupper Executive Vice President and Chief Financial Officer Dated: December 30, 2025

View Full Filing

View this 8-K filing on SEC EDGAR